Matinas BioPharma (MTNB) Announces Chairman Succession Plan

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform delivery technology, today announced its leadership succession plan, with the Board of Directors unanimously appointing current board member, Eric J. Ende, to succeed Herbert J. Conrad as Chairman of the Board. Mr. Conrad, the founding Chairman of Matinas will remain on the Board as an independent director of the Company. The succession will be effective October 1, 2022.

“This change is representative of the progress we have made as a Company,” commented Herbert J. Conrad, Chairman of Matinas. “My future role at Matinas as a continuing member of a talented and dedicated board providing guidance and direction to our strong management team led by Jerry Jabbour is one that I eagerly look forward to. Eric Ende is uniquely qualified to assume the role of Chairman and I am thrilled that he will take over the leadership reins. Eric’s extensive board, industry, and deal experience, combined with his scientific and strategic insights, will be invaluable to Matinas during this exciting phase of development and growth.”

“I am honored to be appointed as the next Chairman of the Board at Matinas,” stated Eric J. Ende. “I could not be more excited about our technology, our leadership team, and the prospects for a truly differentiated platform drug delivery technology. Since I joined the Board in early 2017, I have learned a tremendous amount from Herb and my other colleagues. While it’s a challenge to succeed such an accomplished leader, I am pleased that we will all continue to benefit from Herb’s involvement, and I am looking forward to working more closely with Jerry as we position Matinas for potentially great things in the near and longer term.”

Dr. Ende joined the Company’s Board of Directors in March 2017. Dr. Ende was a director on Genzyme’s Board from 2010 – 2011 until it was acquired by Sanofi-Aventis for $21B in 2011. Dr. Ende is currently on the Board of Directors of Avadel plc, where he is the Chairman of the Nomination & Corporate Governance Committee and is serving on the Audit Committee. Dr. Ende is also on the Technology Transfer Committee of Mount Sinai Innovation Partners.

From 2002 through 2008, Dr. Ende was the senior biotechnology analyst at Merrill Lynch. During Dr. Ende’s career as a biotechnology analyst, he was named to Institutional Investor’s All-America Equity Research Team six times as well as to The Greenwich Survey list of top analysts. He was also named Top Stock Picker by The Street.com and Best Earnings Estimator by Forbes.com.

Dr. Ende received an MBA in Finance & Accounting from NYU – Stern Business School, an MD from Mount Sinai School of Medicine, and a BS in Biology and Psychology from Emory University.

You May Also Be Interested In

• Strathmore Plus Uranium names Richard Newbury to its board
• BofA cites AI exposure as convertible bonds outperform stocks
• Duolingo names Sallie Krawcheck to its board of directors